Strontium ranelate in the treatment of osteoporosis
dc.contributor.author | Hough S. | |
dc.date.accessioned | 2011-05-15T16:16:58Z | |
dc.date.available | 2011-05-15T16:16:58Z | |
dc.date.issued | 2006 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Editorial | |
dc.identifier.citation | Journal of Endocrinology, Metabolism and Diabetes of South Africa | |
dc.identifier.citation | 11 | |
dc.identifier.citation | 1 | |
dc.identifier.issn | 16089677 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/14012 | |
dc.subject | alendronic acid | |
dc.subject | bisphosphonic acid derivative | |
dc.subject | estrogen derivative | |
dc.subject | fluoride | |
dc.subject | parathyroid hormone[1-34] | |
dc.subject | placebo | |
dc.subject | strontium ranelate | |
dc.subject | bone density | |
dc.subject | cell activity | |
dc.subject | cell differentiation | |
dc.subject | cell proliferation | |
dc.subject | clinical trial | |
dc.subject | dermatitis | |
dc.subject | diarrhea | |
dc.subject | drug blood level | |
dc.subject | drug efficacy | |
dc.subject | drug mechanism | |
dc.subject | drug safety | |
dc.subject | drug tolerability | |
dc.subject | dual energy X ray absorptiometry | |
dc.subject | editorial | |
dc.subject | fragility fracture | |
dc.subject | gastrointestinal toxicity | |
dc.subject | headache | |
dc.subject | human | |
dc.subject | nausea | |
dc.subject | nonhuman | |
dc.subject | ossification | |
dc.subject | osteoblast | |
dc.subject | osteoclast | |
dc.subject | osteolysis | |
dc.subject | osteomalacia | |
dc.subject | osteopenia | |
dc.subject | osteoporosis | |
dc.subject | postmenopause osteoporosis | |
dc.subject | thromboembolism | |
dc.subject | treatment outcome | |
dc.title | Strontium ranelate in the treatment of osteoporosis | |
dc.type | Editorial |